Ruxo-BEAT trial (#593)
Laufzeit: 01.01.2017 - 31.12.2040
imported
Kurzfassung
Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia
Laufzeit: 01.01.2017 - 31.12.2040
Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia